Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Moyez Jiwa, Patricia M. Davidson, Phillip J. Newton, Michelle L. Digiacomo, Sarah J. McGrath, Cornelius J. Lotriet
Background : Lung cancer is the leading cause of cancer death in Australia, with only modest improvements in survival. This study aims to identify factors impacting on diagnosis and management of lung cancer with particular reference to Australian primary car…
Haoping Xu, Rui Guo, Biao Li
Objective: To investigate the feasibility of temporally and spatially restricted Kringle5 expression induced by radiation, as well as the dual effect of radiotherapy and antiangiogenic therapy in lung adenocarcinoma in vitro. Methods: We first constructed rec…
Vijayvel Jayaprakash, Gregory M. Loewen, Samjot S. Dhillon, Kirsten B. Moysich, Martin C. Mahoney, Sai Yendamuri, D. Kyle Hogarth, Mary E. Reid
Background: Computed tomography (CT) and bronchoscopy have been shown to improve the detection rates of peripheral and central lung cancers (LC), respectively. However, the performance of the combination of CT and bronchoscopy in detecting LC, in high-risk pa…
Megumi Ishimura, Mika Sakurai-Yageta, Tomoko Maruyama, Tomoko Ando, Masashi Fukayama, Akiteru Goto, Yoshinori Murakami
A tumor suppressor gene, CADM1, encoding an immunoglobulin superfamily cell adhesion molecule, is inactivated in various cancers, including non-small-cell lung cancer (NSCLC). Although promoter methylation is one of the mechanisms to suppress CADM1 expression…
Anne Winther Larsen, Azza A. Khalil, Peter Meldgaard, Marianne M. Knap
Background: The purpose of this study was to evaluate the use of 18 FDG-PET/CT in staging procedure, the pattern of failure and survival in patients with small-cell lung cancer limited disease (LD-SCLC) undergoing chemo-radiotherapy. Methods: A total of 79 LD…
Vijayvel Jayaprakash, Gregory M. Loewen, Martin C. Mahoney, Samjot Dhillon, Sai Yendamuri, D. Kyle Hogarth, Enrique Machare-Delgado, Ravi J. Menezes, Sandra M. Jacob, Mary E. Reid
Background: Chronic obstructive pulmonary disease (COPD) and presence of endobronchial premalignant lesions (EPL) are individual risk factors for lung cancer (LC). However, effect of impaired lung function (ILF) on the natural history of EPL has not been expl…
Francesco Fiorica, Antonio Stefanelli, Silvia Princivalle, Giuliana Pascale, Francesco Cartei
More than 60% of lung cancer patients in Europe and the USA are older than 65 years at the time of diagnosis. Despite this, elderly patients are generally under-represented in clinical trials. That being so, a general consensus on how to treat elderly patient…
Lei Xu, Guang Gao, Jiangong Ren, Fei Su, Zhang Weihua
Estrogen receptors (ERα and ERβ) in the brain play critical roles in maintaining brain tissue homeostasis and in tissue repair after injury. Growth of cancer metastasis in the brain is a constant damaging process. The role of ERs of the host in the progressio…
Alba Mayerly Alvarez, Sandra Janneth Perdomo Lara, Diana M. Palacios, Edward Fabián Carrillo, Luis Gerardo García Herreros, Fidel Camacho Durán, Paulina Ojeda León, Fabio A. Aristizábal
The increase in the number of gene copies at specific loci is a genetic alteration frequently associated with over expression of the related protein in cancer cells. Genes whose dose is consistently augmented in cancer include those involved in cell cycle con…
Lucia D’Amico, Enrico Ruffini, Riccardo Ferracini, Ilaria Roato
Cancer induces tolerance by suppressing immune function, modulating the T helper activity and causing an imbalance of cytokines produced by T cells. IL-12 is an immune regulatory cytokine with potent anti-tumor activity and its signalling network leads to pol…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).